The purpose of this study is to evaluate long-term safety and efficacy of povorcitinib in participants with moderate to severe hidradenitis suppurativa who completed the 54 weeks of study treatment within the originating parent Phase 3 studies (INCB 54707-301 \[NCT05620823\] or INCB 54707-302 \[NCT05620836\]).
Hidradenitis Suppurativa (HS)
The purpose of this study is to evaluate long-term safety and efficacy of povorcitinib in participants with moderate to severe hidradenitis suppurativa who completed the 54 weeks of study treatment within the originating parent Phase 3 studies (INCB 54707-301 \[NCT05620823\] or INCB 54707-302 \[NCT05620836\]).
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa
-
Investigative Site US303, Phoenix, Arizona, United States, 85006
Investigator Site US240, Scottsdale, Arizona, United States, 85255
Investigative Site US307, Fort Smith, Arkansas, United States, 72916
Investigative Site US214, Rogers, Arkansas, United States, 72758
Investigative Site US315, Laguna Niguel, California, United States, 92677
Investigator Site US223, Los Angeles, California, United States, 90033
Investigative Site US222, Oakland, California, United States, 94611
Investigative Site US226, San Diego, California, United States, 92103
Investigative Site US233, Washington, District of Columbia, United States, 20060
Investigative Site US228, Brandon, Florida, United States, 33511
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
For general information about clinical research, read Learn About Studies.
18 Years to
ALL
No
Incyte Corporation,
Incyte Medical Monitor, STUDY_DIRECTOR, Incyte Corporation
2026-12-26